CurtisJudah

How Viagra and Cialis may lower your risk of heart attack and stroke

Health

The life expectancy for men is five years lower than that of women. This may be due to their lower risk of developing cardiovascular disease. Canada Drugs Direct offers a large selection of prescription, non-prescription, and pet-related products. Our discounts and deals are available all year long for both existing and new customers.

We often speak of the efficacy of phosphodiesterase-5 medications (PDE5) for the treatment erectile dysfunction (ED), such as Viagra and Cialis.

There may also be other benefits.

The Journal of the American College of Cardiology published new research that found men who take medications such as Viarga and Cialis, such as those in Vault’s Sex Kit or Libido Kit, may have lower rates of cardiovascular events like strokes and heart attacks. This is a breakthrough finding.

Researchers have found that blood vessel dysfunction in men suffering from cardiovascular disease is not likely to be limited to one part of the body. Endothelial dysfunction (or dysfunction of the inner blood vessels’ inner lining) is more likely to be found in the penis than in the heart. Poor blood flow can lead to endothelial dysfunction, which can prevent erections.

These Medications may help protect against heart attack and stroke

PDE5 inhibitors like Viagra (sildenafil), Cialis (tadalafil), increase the effects of Nitric Ox to relax the penile muscles and expand blood vessels to improve blood flow. This helps men to have better erections.

New research shows that PDE5 inhibitor therapy for ED may also be associated with significantly lower cardiovascular disease risk and death.

See also  Levitra Side Effects and Uses

Researchers compared men suffering from stable CAD to those who received PDE5 inhibitors for ED. They were compared to men with stable CAD receiving Alprostadil for ED. This vasodilator is applied locally and doesn’t have any systemic effects. These were the results. The results?

Although a controlled, randomised trial is needed to determine whether PDE5 inhibitors can be considered cardioprotective or not, early studies show promising evidence that these drugs may save lives and improve sexual function.